{"nctId":"NCT02114151","briefTitle":"Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis","startDateStruct":{"date":"2014-04"},"conditions":["Hepatitis C Virus Infection"],"count":103,"armGroups":[{"label":"Arm 1 (Simeprevir/Sofosbuvir)","type":"EXPERIMENTAL","interventionNames":["Drug: Simeprevir","Drug: Sofosbuvir"]}],"interventions":[{"name":"Simeprevir","otherNames":[]},{"name":"Sofosbuvir","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Hepatitis C virus (HCV) genotype 1 infection (confirmed at screening).\n* HCV ribonucleic acid (RNA) greater than 10,000 IU/mL at screening\n* Treatment-experienced participants must have at least 1 documented previous course of interferon-based regimen with or without ribavirin\n* Participants must have an hepatic imaging procedure (ultrasound, computerized tomography scan or magnetic resonance imaging scan) within 6 months prior to the screening visit (or between screening and Day 1) with no findings suspicious for hepatocellular carcinoma\n* Participant must be willing and able to comply with the protocol requirements\n* Participants with liver cirrhosis\n\nExclusion Criteria:\n\n* Evidence of clinical hepatic decompensation (history or current evidence of ascites, bleeding varices or hepatic encephalopathy)\n* Infection/co-infection with HCV non-genotype 1\n* Co-infection with human immunodeficiency virus (HIV) type 1 or type 2 (HIV-1 or HIV-2) (positive HIV-1 or HIV-2 antibodies test at screening)\n* Co-infection with hepatitis B virus (hepatitis B-surface-antigen positive)\n* Previously been treated with any direct acting anti-HCV agent (approved or investigational) for chronic HCV infection","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With a Sustained Virologic Response (SVR) 12 Weeks After the Actual End of Treatment (EOT)","description":"Participants with hepatitis C virus (HCV) ribonucleic acid (RNA) less than (\\<) 25 international unit per milliliter (IU/mL) (detectable or undetectable) at 12 weeks after the actual end of treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Sustained Virologic Response (SVR) 4 Weeks After the Actual End of Treatment (EOT)","description":"Participants with hepatitis C virus (HCV) ribonucleic acid (RNA) less than (\\<) 25 international unit per milliliter (IU/mL) (detectable or undetectable) at 4 weeks after the actual end of treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Sustained Virologic Response (SVR) 24 Weeks After the Actual End of Treatment (EOT)","description":"Participants with hepatitis C virus (HCV) ribonucleic acid (RNA) less than (\\<) 25 international unit per milliliter (IU/mL) (detectable or undetectable) at 24 weeks after the actual end of treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With On-treatment Virologic Response","description":"On-treatment virologic response was determined by HCV RNA results satisfying a specified threshold. \\<LLOQ undetectable was considered as threshold at any time point. The LLOQ value is 25 IU/mL. EOT=End of Treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With On-treatment Failure","description":"On-treatment failure is defined as participants who do not achieve SVR12 and with confirmed detectable HCV RNA at the actual end of study drug treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Viral Breakthrough","description":"Viral breakthrough was defined as confirmed greater than (\\>) 1 log10 increase in HCV RNA from nadir or confirmed HCV RNA \\>100 IU/mL in participants who had previously achieved HCV RNA \\< LLOQ (25 IU/mL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Viral Relapse","description":"Viral relapse was defined as participants who did not achieve SVR12 and had HCV RNA \\< LLOQ (25 IU/mL) undetectable at EOT and had HCV RNA \\>= LLOQ (25 IU/mL) during the follow-up period.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Hepatitis C Symptom and Impact Questionnaire Version 4 (HCV-SIQv4) Overall Body System Score (OBSS) up to Follow-up Week 12","description":"The HCV-SIQv4 OBSS was a self-administered questionnaire that contained 33 items: 29 questions developed to assess severity or frequency of symptoms associated with HCV or its treatment, 3 questions regarding the impact of symptoms on work/school attendance, and 1 question regarding the impact of symptoms on daily activities. A symptom severity score (the mean of responses to the 29 symptom items); each symptom score was transformed to have a range from 0 to 100 (most severe). Higher HCV SIQv4 scores indicates worse symptom severity, more time missed from work/school, and more impairment in daily activities, respectively.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","spread":"1.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.9","spread":"1.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.7","spread":"1.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.8","spread":"1.36"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fatigue Severity Score (FSS) up to Follow-up Week 24","description":"The FSS was a self-administered questionnaire with 9 items developed to assess disabling fatigue that has been used extensively in studies of chronic HCV infection. Item responses were measured on a 7-point Likert scale ranging from strongly disagree (1 point) to strongly agree (7 points). The 9 items were averaged to produce a total score; a lower total score indicates less severe fatigue. FSS scores have a range from 1 to 7 where higher scores indicate more severe fatigue.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"0.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"0.18"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Depression by Using Center for Epidemiologic Studies Depression Scale (CES-D)","description":"The CES-D Scale assessed how often during the past week participants experienced 20 symptoms commonly associated with major depression. The CES-D scores range from 0 (no symptoms) to 60 (all 20 symptoms most or all of the time during the past 5 to 7 days). The CES-D scores between 16 and 23 points indicate mild to moderate depressive illness while CES-D scores \\>=23 indicate probable major depressive illness.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in EuroQol 5 Dimension Questionnaire (EQ-5D) up to Follow-up Week 24","description":"The EQ-5D questionnaire was a brief, generic health-related quality of life (HRQOL) assessment that could also be used to incorporate participant preferences into health economic evaluations. The EQ-5D questionnaire assessed HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a \"thermometer\" visual analog scale with response options ranging from 0 (worst imaginable health) to 100 (best imaginable health).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.1","spread":"2.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":"1.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":"1.75"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Not Achieving SVR Showing Emerging Mutation at Time of Failure in HCV NS3/4A Sequence and NS5B up to Follow-up Week 24","description":"Sequencing of the HCV nonstructural protein 3/4A (NS3/4A) and nonstructural protein 5B (NS5B) genes was done to identify pre-existing sequence polymorphisms and characterize emerging HCV viral variants in participants not achieving SVR. Sequencing data is available for 16 participants.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":103},"commonTop":["Fatigue","Headache","Nausea","Pruritus","Constipation"]}}}